UCB Acquire Zogenix 2022 Capital Markets Conference

UCB announced its acquisition of Zogenix, a biopharmaceutical company focused on epilepsy treatments. The transaction was presented to capital markets on January 19, 2022, detailing the merger agreement structure and expected benefits for both companies' epilepsy portfolios.